Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?

Antibodies to human CTLA-4 have been shown to induce long-lasting protection against melanoma. It is assumed that these antibodies cause tumor rejection by blocking negative signaling from the B7-CTLA-4 interactions to enhance priming of naïve T cells in the lymphoid organs. Recently, we reported th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Fei, Du, Xuexiang, Liu, Mingyue, Zheng, Pan, Liu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907314/
https://www.ncbi.nlm.nih.gov/pubmed/29713453
http://dx.doi.org/10.1186/s13578-018-0229-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907314/
https://www.ncbi.nlm.nih.gov/pubmed/29713453
http://dx.doi.org/10.1186/s13578-018-0229-z

Ejemplares similares